Lenperone (Elanone-V) is a typical antipsychotic of the butyrophenone chemical class.[1] It was first reported as an anti-emetic in 1974,[2] and its use in treatment of acute schizophrenia was reported in 1975.[1] Related early antipsychotic agents include declenperone and milenperone.
Clinical data | |
---|---|
Trade names | Elanone-V |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.042.166 |
Chemical and physical data | |
Formula | C22H23F2NO2 |
Molar mass | 371.428 g·mol−1 |
3D model (JSmol) |
|
| |
|
Lenperone was never approved by the FDA for use in humans in the United States,[3] but prior to 1989 it was approved for use in veterinary medicine for sedation.[4][5][6]
The alkylation between 2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane [3308-94-9] (1) and 4-(4-fluorobenzoyl)piperidine [56346-57-7] (2) gives 2-(p-fluorophenyl)-2-{3-[4-(p-fluorobenzoyl)piperidino]propyl}-1,3-dioxolane, CID:20318874 (3). Deprotection of the ketal function completes the synthesis of lenperone (4).
Chemically related drugs containing the same 4-(p-fluorobenzoyl)piperidine group:
Table 1. Marketed butyrophenones with approval status and indication
The firm requested withdrawal of approval because the products are no longer being marketed. Effective date: July 13, 1989